19 Healthcare Stocks Moving In Thursday's Pre-Market Session

Gainers

• Exicure, Inc. XCUR stock increased by 27.4% to $3.12 during Thursday's pre-market session. The market value of their outstanding shares is at $198.3 million. The most recent rating by H.C. Wainwright, on November 06, is at Buy, with a price target of $8.00.
• ObsEva, Inc. OBSV stock rose 8.6% to $2.91. The market value of their outstanding shares is at $339.3 million. The most recent rating by Credit Suisse, on November 08, is at Neutral, with a price target of $4.00.
• Acasti Pharma, Inc. ACST shares rose 4.8% to $2.16. The market cap seems to be at $209.4 million. The most recent rating by B. Riley FBR, on August 29, is at Buy, with a price target of $7.75.
• Qiagen, Inc. QGEN stock rose 3.2% to $36.64. The market cap seems to be at $6.7 billion. According to the most recent rating by Kepler Cheuvreux, on October 09, the current rating is at Reduce.
• SINTX Technologies, Inc. SINT shares increased by 3.1% to $2.00. The market cap stands at $4.8 million.
• Clovis Oncology, Inc. CLVS stock surged 2.9% to $6.74. The market cap seems to be at $173.7 million. The most recent rating by Goldman Sachs, on October 08, is at Sell, with a price target of $3.00.
• Replimune Group, Inc. REPL shares rose 2.9% to $14.00. The market cap seems to be at $539.2 million. The most recent rating by Roth Capital, on September 04, is at Buy, with a price target of $20.00.
• Diffusion Pharmaceuticals, Inc. DFFN shares increased by 2.4% to $0.26. The market value of their outstanding shares is at $3.9 million.
• Reata Pharmaceuticals, Inc. RETA stock surged 1.3% to $190.00. The market value of their outstanding shares is at $6.2 billion. The most recent rating by Citigroup, on November 12, is at Buy, with a price target of $328.00.

Losers

• Lipocine, Inc. LPCN shares decreased by 34.2% to $0.45 during Thursday's pre-market session. The market cap stands at $66.8 million.
• Jaguar Health, Inc. JAGX shares plummeted 14.4% to $0.89. The market cap seems to be at $8.0 million. The most recent rating by Ladenburg Thalmann, on September 12, is at Buy, with a price target of $5.00.
• Fulgent Genetics, Inc. FLGT shares declined 12.0% to $12.00. The market cap seems to be at $178.8 million. The most recent rating by Piper Jaffray, on November 05, is at Overweight, with a price target of $12.30.
• Canopy Growth, Inc. CGC shares decreased by 6.5% to $17.30. The market value of their outstanding shares is at $11.0 billion. The most recent rating by Piper Jaffray, on October 22, is at Overweight, with a price target of $36.00.
• OrganiGram Holdings, Inc. OGI stock declined 5.2% to $2.38. The market value of their outstanding shares is at $710.5 million.
• BioCryst Pharmaceuticals, Inc. BCRX shares plummeted 3.1% to $1.55. The market cap seems to be at $220.8 million.
• Aurora Cannabis, Inc. ACB stock fell 2.3% to $3.46. The market cap stands at $6.3 billion. The most recent rating by Piper Jaffray, on October 22, is at Neutral, with a price target of $4.00.
• Cronos Group, Inc. CRON stock fell 1.6% to $7.14. The market cap seems to be at $3.6 billion. The most recent rating by Bank of America, on November 13, is at Buy, with a price target of $15.00.
• BioLine Rx, Inc. BLRX stock decreased by 1.5% to $2.63.
• GlaxoSmithKline, Inc. GSK stock fell 1.2% to $44.12. The most recent rating by Argus Research, on November 11, is at Buy, with a price target of $50.00.